DDInter649 DDInter1491
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile,
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Enzalutamide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Enzalutamide {u} (Compound) causes {v} (Side Effect) Neutropenia
Neutropenia {u} (Side Effect) is caused by {v} (Compound) Pomalidomide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Enzalutamide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Enzalutamide {u} (Compound) causes {v} (Side Effect) Neutropenia
Neutropenia {u} (Side Effect) is caused by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Pomalidomide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Enzalutamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pomalidomide (Compound)
Enzalutamide (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Pomalidomide (Compound)
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide (Compound) resembles Pomalidomide (Compound)
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Enzalutamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Enzalutamide (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Pomalidomide (Compound)
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pomalidomide (Compound)
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)